Anandamide — the bliss molecule

TL;DR

• Name from Sanskrit ānanda ('bliss').
• On-demand synthesis from membrane phospholipids (NAPE-PLD).
• Degraded by FAAH within minutes.
• Runner's high correlates with anandamide levels (Fuss 2015).

Why is anandamide so short-lived?

Unlike classical neurotransmitters anandamide is not vesicularly stored but synthesised on demand and rapidly hydrolysed by FAAH. This on-demand kinetics keeps the ECS a fine modulator rather than a chronic driver (Mechoulam & Parker 2013).

Physiological mode of action and receptor interaction

Anandamide exerts its physiological effects primarily through the endocannabinoid system by binding as a partial agonist to the CB1 and CB2 cannabinoid receptors. Its affinity for the CB1 receptor, which is primarily located in the central nervous system, significantly exceeds that for the peripheral CB2 receptor. Through this binding, the lipid modulates the release of neurotransmitters such as glutamate and gamma-aminobutyric acid. This backward-directed signaling pathway, also referred to as retrograde synaptic transmission, enables the nervous system to dampen overexcitation and maintain neuronal balance.

In addition to the classical cannabinoid receptors, the body's endogenous molecule also interacts with other receptor systems in the organism. Particularly noteworthy is the activation of the TRPV1 receptor, which is partly responsible for the perception of thermal stimuli and pain signals. This interaction illustrates that anandamide is involved in complex sensory processes far beyond pure mood regulation. Physiological research is intensively investigating how the interplay of these different signaling pathways contributes to pain modulation and the management of physical and psychological stress.

• Preferred binding to CB1 receptors in the central nervous system for neuronal dampening
• Retrograde signaling for the precise control of neurotransmitter release
• Interaction with TRPV1 receptors to influence pain and temperature sensations
• Involvement in cellular homeostasis and the body's own stress management

Clinical relevance and the concept of endocannabinoid deficiency

In medical research, the hypothesis of clinical endocannabinoid deficiency is being discussed. If the organism continuously synthesizes insufficient amounts of anandamide or if the molecule is degraded too quickly by the FAAH enzyme, this can lead to dysregulation. Scientists suspect that such a deficiency correlates with various chronic conditions such as migraines, fibromyalgia, or irritable bowel syndrome. However, the exact causal relationships have not yet been fully deciphered, which is why the medical community continues to conduct intensive basic research into this.

Since the direct administration of synthetic anandamide is hardly feasible therapeutically due to rapid enzymatic degradation, medical approaches focus on indirectly influencing endocannabinoid tone. In addition to researching enzyme inhibitors, studies are examining the extent to which plant-derived cannabinoids or non-pharmacological interventions, such as endurance sports and specific dietary habits, can stabilize anandamide levels. These approaches aim to gently support the body's own regulatory capacity without directly oversaturating the receptors.

• Hypothesis of clinical endocannabinoid deficiency in chronic pain syndromes
• Link between accelerated FAAH degradation and reduced stress resilience
• Focus on indirect therapeutic methods instead of direct anandamide substitution
• Investigation of lifestyle factors for the natural regulation of endocannabinoid tone

Classification within Swiss legislation and medical practice

The medical use of cannabinoids in Switzerland is directly related to the functioning of anandamide. Since August 2022, medical cannabis has been prescribable by doctors in Switzerland without an FOPH exceptional licence. The THC it contains acts as an exogenous analogue to anandamide, as it binds to the same CB1 receptors. In contrast to short-lived anandamide, however, THC is not broken down by FAAH, which leads to a significantly more intense and longer-lasting effect. In road traffic, a strict zero-tolerance policy applies due to the psychoactive effect, with a detection limit of 1.5 micrograms of THC per litre of blood.

For over-the-counter products, a limit of less than one percent total THC applies in Switzerland in order not to fall under the Narcotics Act. Such CBD-rich products are frequently used by consumers to enhance well-being, with CBD suspected of delaying the breakdown of anandamide. The responsible federal offices, such as the FOPH and Swissmedic, strictly monitor the safety of these products. At the same time, the ongoing Swiss pilot trials provide valuable scientific data on how the controlled consumption of cannabis affects the body's own endocannabinoid system.

• Medical cannabis prescribable by doctors since August 2022 without an FOPH exceptional licence
• THC as an exogenous analogue to anandamide with a significantly longer half-life
• Strict limit of 1.5 micrograms per litre of blood in Swiss road traffic for THC consumption
• Accompanying scientific research within the framework of cantonal pilot trials on the endocannabinoid system

FAQ